Dr. Xiaofan Zhu is the Chief Clinical Expert at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. As a senior consultant physician and doctoral supervisor, she specializes in the precision diagnosis and treatment of pediatric hematologic malignancies, with a strong focus on translational research and novel therapeutic strategies. Dr. Zhu currently serves as Vice Chair of the National Health Commission Expert Committee on Pediatric Leukemia, Chair-Elect of the Pediatric Oncology Committee of the Chinese Anti-Cancer Association, and Principal Investigator of the CCCG-2025-ALL national collaborative research initiative. She is also a member of the editorial boards of Chinese Journal of Pediatrics and Chinese Journal of Hematology. She has published extensively as first or corresponding author in leading international journals such as The Lancet Oncology, JAMA Oncology, Nature Genetics, Nature Cell Biology, and Blood. Her research is supported by multiple national funding programs, including the National Key R&D Program and grants from the National Natural Science Foundation of China. Dr. Zhu's contributions to clinical and academic medicine have been recognized with numerous honors, including the National Science and Technology Progress Award (Second Prize), Soong Ching Ling Pediatric Medicine Award, and Tianjin Natural Science First and Third Prizes.
Ph.D., Internal Medicine, Hokkaido University, Hokkaido, Japan, 1994–1996
Bachelor's Degree, Internal Medicine, Bethune Medical University, Changchun, China, 1981–1986
Chief Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2006–
Associate Chief Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1998–2006
Attending Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1986–1998
PRINCIPAL HONORS, AWARDS:
2021 The Second Prize of the National Natural Science Award
2019 Soong Ching Ling Pediatric Medicine Award
2017 Third Prize of Tianjin Natural Science Award
2015 First Prize of Tianjin Natural Science Award
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2023–2026 Vice Chair, National Health Commission Expert Committee on Pediatric Leukemia
2022–2025 Chair-Elect, Pediatric Oncology Committee, Chinese Anti-Cancer Association
2025–present Principal Investigator of CCCG-2025-ALL, Children's Cancer Group, Chinese Anti-Cancer Association
SELECTED PUBLICATIONS:
1. Yang, Wenyu*; Cai, Jiaoyang*; Shen, Shuhong*; Gao, Ju*; Yu, Jie*; Hu, Shaoyan*; Jiang, Hua; Fang, Yongjun; Liang, Changda; Ju, Xiuli; Wu, Xuedong; Zhai, Xiaowen; Tian, Xin; Wang, Ningling; Liu, Aiguo; Jiang, Hui; Jin, Runming; Sun, Lirong; Yang, Minghua; Leung, Alex W. K.; Pan, Kaili; Zhang, Yingchi; Chen, Jing; Zhu, Yiping; Zhang, Hui; Li, Chunfu; Yang, Jun J.; Cheng, Cheng#; Li, Chi-Kong#; Tang, Jingyan#; Zhu, Xiaofan#; Pui, Ching-Hon# ; Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015) an open-label, multicentre, randomised, phase 3 non-inferiority trial, Lancet Oncology, 2021, 22(9): 1322-1332
2. Shuhong Shen*; Xiaojuan Chen*; Jiaoyang Cai*; Jie Yu; Ju Gao; Shaoyan Hu; Xiaowen Zhai; Changda Liang; Xiuli Ju; Hua Jiang; Runming Jin; Xuedong Wu; Ningling Wang; Xin Tian; Kaili Pan; Hui Jiang; Lirong Sun; Yongjun Fang; Chi-kong Li; Qun Hu; Minghua Yang; Yiping Zhu; Hui Zhang; Chunfu Li; Deqing Pei; Sima Jeha; Jun J Yang; Cheng Cheng#; Jingyan Tang#; Xiaofan Zhu#; Ching-Hon Pui# ; Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia, JAMA Oncology, 2020, 6(3): 358-366
3. Runxia Gu*; Fang Liu*; Dehui Zou*; Yingxi Xu; Yang Lu; Bingcheng Liu; Wei Liu; Xiaojuan Chen; Kaiqi Liu; Ye Guo; Xiaoyuan Gong; Rui Lv; Xia Chen; Chunlin Zhou; Mengjun Zhong; Huijun Wang; Hui Wei; Yingchang Mi; Lugui Qiu; Lulu Lv; Min Wang; Ying Wang#; Xiaofan Zhu#; Jianxiang Wang#; Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia, Journal of Hematology & Oncology, 2020, 13(1)
4. Tang, Jingyan; Yu, Jie*; Cai, Jiaoyang*; Zhang, Li*; Hu, Shaoyan*; Gao, Ju*; Jiang, Hua; Fang, Yongjun; Liang, Changda; Ju, Xiuli; Jin, Runming; Zhai, Xiaowen; Wu, Xuedong; Tian, Xin; Hu, Qun; Wang, Ningling; Jiang, Hui; Sun, Lirong; Leung, Alex W. K.; Yang, Minghua; Pan, Kaili; Cheng, Cheng; Zhu, Yiping; Zhang, Hui; Li, Chunfu; Yang, Jun; Li, Chi-kong#; Zhu, Xiaofan#; Shen, Shuhong#; Pui, Ching-Hon# ; Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation, BLOOD, 2021, 138(1): 331-343
5. Yingchi Zhang*; Shicheng Wang*; Jingliao Zhang*; Chao Liu*; Xinqi Li; Wenbo Guo; Yongjuan Duan; Xiaoyan Chen; Suyu Zong; Jiarui Zheng; Yixuan Wu; Xiaoli Chen; Xuelian Cheng; Yanxia Chang; Yue Wang; Feng Ding; Wenyu Yang; Xiaojuan Chen; Ye Guo; Li Zhang; Yumei Chen; Yao Zou; Xiaofan Zhu#; Jin Gu#; Tao Cheng# ; Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis, Nature Cell Biology, 2022, 24: 242-252